Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 12018 | 0.6802 |
09:34 ET | 100 | 0.68 |
09:36 ET | 960 | 0.6869 |
09:38 ET | 1396 | 0.68 |
09:39 ET | 5100 | 0.6893 |
09:41 ET | 5182 | 0.685 |
09:43 ET | 100 | 0.68 |
09:45 ET | 1024 | 0.68 |
09:48 ET | 559 | 0.68 |
09:50 ET | 100 | 0.68 |
09:52 ET | 1810 | 0.693 |
09:54 ET | 100 | 0.68 |
09:56 ET | 100 | 0.68 |
09:59 ET | 100 | 0.68 |
10:01 ET | 3084 | 0.6935 |
10:03 ET | 873 | 0.69 |
10:06 ET | 1145 | 0.6868 |
10:08 ET | 200 | 0.68335 |
10:10 ET | 4526 | 0.68 |
10:14 ET | 300 | 0.6816 |
10:15 ET | 12568 | 0.6836 |
10:17 ET | 500 | 0.6917 |
10:21 ET | 200 | 0.6935 |
10:24 ET | 584 | 0.692692 |
10:26 ET | 100 | 0.6934 |
10:28 ET | 200 | 0.6934 |
10:30 ET | 100 | 0.6934 |
10:32 ET | 200 | 0.69 |
10:33 ET | 100 | 0.6934 |
10:37 ET | 200 | 0.6934 |
10:39 ET | 400 | 0.6934 |
10:42 ET | 100 | 0.69 |
10:46 ET | 1399 | 0.6934 |
10:48 ET | 300 | 0.69 |
10:53 ET | 200 | 0.6934 |
10:55 ET | 100 | 0.6917 |
10:57 ET | 784 | 0.69 |
11:00 ET | 100 | 0.6934 |
11:04 ET | 7041 | 0.6866 |
11:09 ET | 435 | 0.6831 |
11:11 ET | 300 | 0.684 |
11:13 ET | 3500 | 0.68 |
11:18 ET | 300 | 0.68 |
11:20 ET | 400 | 0.6929 |
11:26 ET | 300 | 0.68 |
11:29 ET | 400 | 0.68 |
11:31 ET | 100 | 0.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 36.7M | -0.3x | --- |
ImmuCell Corp | 35.4M | -8.9x | --- |
Aadi Bioscience Inc | 45.2M | -0.7x | --- |
Turnstone Biologics Corp | 60.1M | -0.8x | --- |
Prenetics Global Ltd | 70.4M | -1.3x | --- |
SQZ Biotechnologies Co | 752.0K | 0.0x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.7M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.